Genoa Ventures is a seed-stage fund led by PhD geneticist Jenny Rooke that focuses on bioconvergence—investing in tools, platforms, and technologies that enable biology rather than traditional drug development companies. The fund positions itself as more resilient during biotech downturns since life science tools remain essential infrastructure that pharma and biotech companies still need regardless of market conditions.